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Results: Progressive histopathologic changes characteristic of devel-
oping OA were observed concomitantly with aging. This change was
initiated by the disruption of the weight-bearing regions of articular
cartilage at 6 months of age, and subsequent changes such as cloning
of chondrocytes or loss of Safranin-O staining were recognized from
8 months of age onward. The ﬁgure shows the Mankin scores obtained
from sections stained with Safranin-O. As shown in this ﬁgure, the scores
were increased with aging in both groups. Statistical signiﬁcance was
recognized between two groups only in the early phase at 6 months
(p = 0.032). This data was consistent with the data of gross appearance.
Conclusions: The present study demonstrated that menaquinones could
delay the progression of osteoarthritis. To our knowledge, this is the ﬁrst
report to discuss the effect of menaquinones on the pathological feature
of OA.
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Purpose: To evaluate the efﬁcacy and tolerability of one single hyaluronic
acid (Adant®) intra articular (IA) injection for hip osteoarthritis (OA).
Methods: A randomised, double-blind (investigator blinded to the proce-
dure), placebo-controlled trial. Patients (age over 30) with symptomatic
hip OA (pain level on VAS >40mm), Kellgren Lawrence grade II or III, were
randomly allocated to receive one ﬂuoroscopically guided IA injection of
hyaluronic acid (2.5ml) or placebo (2.5ml). Patients were followed up
every month for 3 months. The mean outcome measure was the level
of pain recorded on a VAS (0–100mm) at month 3 and compared with
baseline. Secondary outcomes included the percentage of responders
according to the OMERACT-OARSI criteria, the Western Ontario and
McMaster Universities (WOMAC) OA index subscores on pain, stiffness
and disability, the patient’s and physician’s global assessments. Safety
was assessed at each visit. Statistical analysis was performed on the
inter-group difference in the intent-to-treat population (ITT) and in the per
protocol (PP) population. Missing data were replaced by carrying forward
the last outcome.
Results: Eighty-ﬁve patients were included, and were randomized in the
hyaluronic acid group (n = 42) or in the placebo group (n = 43). Baseline
characteristics were similar between the two groups. The number of drops
out was 5% (n=4). At end point, the decrease in pain was −7.8 (24.95)
and −9.12 (27.37) in the hyaluronic acid and placebo groups respectively,
in the ITT population (p = 0.98). Same result was found in PP analysis.
The OMERACT-OARSI responder rate was 33.3% in the hyaluronic acid
group and 32.5% in the placebo group (p = 0.94). There was no signiﬁcant
difference, both in ITT and in PP analysis, in secondary end points as well
as in the consumption of rescue medication between placebo and verum.
There was no difference in the frequency of adverse events between
groups.
Conclusions: This study failed to show a superior symptomatic effect
of a single IA hyaluronic acid injection (Adant®) over placebo in patients
with hip OA. Further studies are required to explore the potential efﬁcacy
of more than one single intra articular injection in hip OA.
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Purpose: Elucidate if a daily common clinical administration of two
intraarticular drugs as Hyaluronic Acid (H.A.) used to treat osteoarthrosis
and Bupivacaine used as local anaesthesia, cause increase degradation
of Hyaluronic Acid.
Methods: In vitro studies with ﬁve commercial H.A. have been used for
this study, (Synvisc®, Coxarthrum®, Go-on®, Hyalgan® and Durolane®)
with Bupivacaine at three different concentrations (0.25%, 0.50% and
0.75%) with/without adrenaline (1/200,000), with 24 hours incubation at
4ºC and 37ºC. Cromatography procedures (molecular exclusion HPLC)
have been used for determination of molecular weight and degradation
percentage of H.A. Anova-Manova and Kendall’s correlation have been
used to determinate statistiscal signiﬁcance.
Results: Synvisc® and Durolane® have shown less degradation and
different behavior than Coxarthrum®, Hyalgan® and Go-on® (Kendall’s
correlation p< 0.05). Temperature of incubation modiﬁed the degradation
of H.A. Durolane® and Synvisc® at 4ºC showed higher degradation
than at 37ºC (p< 0.05), otherwise happens for Coxarthrum®, Go-on®
and Hyalgan® that increased degradation at 37ºC (p< 0.05). Higher
concentration of Bupivacaine increased the degradation of H.A. in all
cases (p< 0.05) and the concomitant use of adrenaline increased the
degradation in the three concentrations used at the present study for
Synvisc®, 0.25 and 0.75 for Coxarthrum®, only at 0.75 for Durolane® and
0.25 for Go-on® (p< 0.05). Adrenaline seems not to increase degradation
over Hyalgan.
Conclusions: Bupivacaine administration (with/without adrenaline) with
H.A. must be valued before concomitant intraarticular administration
because Bupivacaine increased H.A degradation of all the H.A. studied.
Durolane® and Synvisc® have shown less degradation (6 to 20%) and
different behavior than Coxarthrum®, Hyalgan®, Go-on® (12 to 20%, 27
to 29% and 28 to 39% respectively). Higher concentration of Bupivacaine
and the concomitant use of adrenaline increased the degradation of H.A.
in all cases except the concomitant use of adrenaline that seems not to
affect Durolane® degradation except at highest Bupivacaine concentra-
tion.
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Purpose: Chondroitin sulfate (CS) is a SYSADOA eliciting an anti-
inﬂammatory effect. Since patients take CS over long periods, it was
of interest to assess whether CS modulates the activity of cytochrome
P450 isoforms (P450).
Methods: Two models were used, chronic intake of CS in control rabbits
and in rabbits with a down-regulated P450 by an inﬂammatory reaction
(IR). Six groups of 5 rabbits were used; three were used to assess the
effect of CS on P450, one without CS and two receiving orally around
20mg/kg/day CS for 20 and 30 days; three groups received turpentine
s.c. generating an aseptic IR (AIR) 48 h before their sacriﬁce, e.g. days
−2, 18 and 28, exposed to CS for 0, 20 or 30 days, respectively. CYP3A6,
CYP1A2 and NADPH P450 reductase (NADPH) activity, expression and
RNAm were assessed in the hepatocytes.
Results: Compared with control rabbits, 20 and 30 days CS did not affect
the activity of CYP3A6, e.g. 15582±1330, 13480±3052 and 14701±841,
and of CYP1A2, e.g. 6532±1203, 11612±2403 and 7494±746, arbitrary
